Fulcrum Therapeutics Shares up 31% After Rival Pfizer Withdraws Sickle Cell Disease Treatment
fulcrum therapeutics股價上漲31%,競爭對手輝瑞撤回鐮刀形細胞病治療
Fulcrum Therapeutics Shares up 31% After Rival Pfizer Withdraws Sickle Cell Disease Treatment
fulcrum therapeutics股價上漲31%,競爭對手輝瑞撤回鐮刀形細胞病治療
譯文內容由第三人軟體翻譯。